KW-6356
Dopaminergic, Motor Function
Investigational compound; human pharmacokinetics not publicly published.
In short
- A second-generation adenosine A2A receptor antagonist and inverse agonist, developed by Kyowa Kirin for Parkinson disease.
- Reached phase 2 trials in Parkinson disease, both as monotherapy and adjunctive to levodopa.
- Its predecessor istradefylline is an APPROVED drug (Nouriast/Nourianz) for Parkinson disease, which gives the class real regulatory precedent.
- Human pharmacokinetics for KW-6356 are not publicly published in detail.
- Interest outside Parkinson disease is speculative — it is a movement-disorder drug candidate, not a nootropic.
Structure
How it works
Adenosine A2A receptors are concentrated in the striatum, where they form heteromers with dopamine D2 receptors and oppose D2 signalling. Blocking A2A therefore indirectly facilitates dopaminergic transmission without acting on dopamine receptors directly.
KW-6356 is described as an inverse agonist rather than a neutral antagonist, meaning it suppresses constitutive receptor activity as well as blocking adenosine — reported to produce more complete pathway suppression than istradefylline.
The appeal in Parkinson disease is improving motor function without adding to the dyskinesia burden that comes from escalating levodopa.
What the research shows
Phase 2 trials in Parkinson disease as monotherapy and as levodopa adjunct have been conducted, with results reported at conferences and in the literature.
Istradefylline, the first-in-class A2A antagonist, is approved in Japan and the US as adjunctive therapy for Parkinson disease with off episodes — establishing that the mechanism produces clinically meaningful benefit.
No evidence supports use for cognition or performance in healthy people. That application is extrapolation from "affects dopamine" rather than from any data.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — phase 2 Parkinson disease trials | Low single-digit milligram once-daily doses; see trial records | oral | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 1–5 mg daily | oral |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. Detailed pharmacokinetics have not been published publicly. Community dosing derives from reported trial dose ranges rather than from any characterisation of what those doses do in a healthy person.
Handling and storage
Oral, once daily in the trial protocols. Sold as powder or capsules in research-chemical channels.
No route, timing, or duration has been established outside the Parkinson trials.
Side effects
The class profile from istradefylline includes dyskinesia (particularly when added to levodopa), nausea, dizziness, hallucinations, and insomnia.
Dyskinesia is the most relevant class effect and reflects the mechanism working — facilitating dopaminergic output in a system already receiving levodopa.
A2A receptors are also present in the cardiovascular and immune systems, so antagonism is not CNS-exclusive. Long-term consequences in healthy people are entirely uncharacterised.
Combinations
No interaction data for healthy use. The clinically relevant interaction is with dopaminergic drugs, where the effect is additive by design and dyskinesia is the manifestation.
Caffeine is a non-selective adenosine antagonist acting on the same receptor family, and the interaction is unstudied but mechanistically real.
Research status
A legitimate pharmaceutical programme by Kyowa Kirin, with the class validated by istradefylline's approval.
The published literature focuses entirely on Parkinson disease. There is no research on cognitive or performance applications.
Legal status
Not approved in any jurisdiction. Investigational. Sold as a research chemical.
WADA status
Not specifically named on the Prohibited List. Falls under WADA class S0, which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Treat it as prohibited in sport.
Conclusion
KW-6356 is a real drug candidate for a real disease, with an approved predecessor demonstrating the mechanism works in Parkinson disease.
None of that says anything about what it does in a healthy brain, and the interest it attracts outside Parkinson disease is inference from mechanism rather than evidence.
Sources
Track your own KW-6356 protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.